
Ask a doctor about a prescription for UROTROL NEO 4 mg PROLONGED-RELEASE HARD CAPSULES
Leaflet: Information for the user
Urotrol Neo 4 mg prolonged-release hard capsules
Tolterodine tartrate
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
If you have any doubts, consult your doctor or pharmacist.
Contents of the leaflet:
The active ingredient in Urotrol Neo is tolterodine. Tolterodine is a medication that belongs to the group of medications called antimuscarinics.
Urotrol Neo is used to treat the symptoms of overactive bladder syndrome. If you have overactive bladder syndrome, you may notice that:
Do not take Urotrol Neo if
Warnings and precautions
Consult your doctor or pharmacist before starting to take Urotrol Neo if you think any of these situations may apply to you.
Other medications and Urotrol Neo
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Tolterodine, the active ingredient in Urotrol Neo, may interact with other medications.
The use of tolterodine in combination with the following medications is not recommended:
Urotrol Neo should be used with caution when administered in combination with:
Taking Urotrol Neo with food and drinks
Urotrol Neo can be taken before, during, or after a meal.
Pregnancy and Breastfeeding
Pregnancy
You should not use Urotrol Neo if you are pregnant. Inform your doctor immediately if you are pregnant, think you may be pregnant, or are planning to become pregnant.
Breastfeeding
It is unknown whether tolterodine is excreted in breast milk. The use of Urotrol Neo during breastfeeding is not recommended.
Consult your doctor or pharmacist before using any medication.
Driving and using machines
Urotrol Neo may make you feel dizzy, tired, or affect your vision; your ability to drive or operate machinery may be impaired.
Urotrol Neo contains sucrose (a type of sugar)
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Dose
Follow the instructions for taking Urotrol Neo exactly as your doctor has indicated. Consult your doctor or pharmacist if you have any doubts.
The recommended dose is one 4 mg capsule per day, except in patients with liver or kidney disease, or bothersome side effects, in which case your doctor may reduce your dose to one 2 mg capsule per day.
The use of Urotrol Neo is not recommended in children.
Urotrol Neo is taken orally. The capsules should be swallowed whole. Do not chew the capsules.
Duration of treatment
Your doctor will indicate the duration of your treatment with Urotrol Neo. Do not stop treatment before if you do not observe an immediate effect, as your bladder needs time to adapt to it. Complete the treatment with the prescribed prolonged-release capsules. If you do not notice any effect, consult your doctor.
The benefit of treatment should be reevaluated after 2-3 months of use.
Always consult your doctor if you are thinking of stopping treatment.
If you take more Urotrol Neo than you should
If you or anyone else takes too many prolonged-release capsules, consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, go to the nearest hospital or consult the Toxicology Information Service, phone 91 562 04 20.
If you forget to take Urotrol Neo
If you forget to take a dose, take it as soon as you can. However, if it is almost time for your next dose, wait for the next dose and take it at the usual time. In this case, continue taking the capsules as your doctor has indicated.
Do not take a double dose to make up for forgotten doses.
If you have any additional questions about the use of this medication, consult your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
You should consult your doctor immediately if you notice symptoms of angioedema, such as:
In addition, you should seek medical attention if you experience a hypersensitivity reaction (e.g., itching, rash, hives, and difficulty breathing). This occurs rarely (less than 1 in 1000 patients).
Inform your doctor or go to the emergency department if you experience:
These may be symptoms of heart failure. This occurs rarely (less than 1 in 1000 patients).
The following side effects have been observed during treatment with Urotrol Neo with the following frequencies.
The very commonside effects that may affect more than 1 in 10 people are:
The commonside effects that may affect at least 1 in 100 people are:
The uncommonside effects that may affect at least 1 in 1000 people are:
Additional reported reactions include severe allergic reactions, confusion, hallucinations, increased heart rate, skin redness, stomach burning, vomiting, angioedema, and dry skin and disorientation. There have been reports of worsening dementia symptoms in patients being treated for dementia.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medication Monitoring System for Human Use: https://www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Blister: Keep the blister in the outer carton.
Bottles: Keep in the original container.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Urotrol Neo
The active ingredient in Urotrol Neo 4 mg prolonged-release capsules is tolterodine. Each capsule contains 4 mg of tolterodine tartrate, which corresponds to 2.74 mg of tolterodine.
The other components are:
Capsule contents: sugar granules (containing sucrose and cornstarch) [see section 2. Urotrol Neo contains sucrose (a type of sugar)], hypromellose, Surelease E-7-19040 transparent (containing ethylcellulose, medium-chain triglycerides, oleic acid).
Capsule: gelatin and colorants.
Colorants: carmine indigo (E132) and titanium dioxide (E171).
Printing ink: Shellac lacquer (E904), titanium dioxide (E171), propylene glycol (E1520), and simethicone.
Appearance of the product and package contents
Urotrol Neo is a prolonged-release capsule designed for once-daily administration.
The Urotrol Neo 4 mg capsules are blue and have a symbol and a "4" printed in white.
Urotrol Neo is available in the following package sizes:
Blister packs:
Bottles: containing 30, 90, and 100 capsules.
Clinical packs containing 80, 160, and 320 capsules are available.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Almirall, S.A.
General Mitre, 151
08022 - Barcelona
Spain
Manufacturer
Pfizer Italia, S.r.l.
Località Marino del Tronto
63100 Ascoli Piceno, Italy
This medication is authorized in the member states of the European Economic Area under the following names:
Protol SR: Sweden
Urotrol Neo: Spain
Date of the last revision of this leaflet: December 2022
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of UROTROL NEO 4 mg PROLONGED-RELEASE HARD CAPSULES in November, 2025 is around 28.58 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for UROTROL NEO 4 mg PROLONGED-RELEASE HARD CAPSULES – subject to medical assessment and local rules.